Hi, the ongoing clinical trial of the RAS inhibitor RMC-6236 includes a requirement for participants to have been previously treated with one prior line of therapy based on 5-fluorouracil (5-FU) or gemcitabine, as well as a certain time interval after surgery. My husband is currently on cycle 12 of the RMC-6236 trial (almost 8 months) and his tumor remains stable. He is stage IV, has not had surgery, and completed 12 cycles of FOLFIRINOX and SBRT before starting the clinical trial.
Currently, several other trials for KRAS mutations are open, and in my opinion, it’s best to discuss these options directly with your oncologist and also contact the Pancreatic Cancer Action Network, which can assist with recommendations for further trial searches based on your husband’s overall condition, prior treatment history, and tumor mutation profile. Their contact number is (877) 297-1862.
Links to their website and the RMC-6236 trial are below:
https://pancan.org/facing-pancreatic-cancer/patient-services/contact-us/
https://www.clinicaltrials.gov/study/NCT06625320.
I hope this helps a bit as you continue to look for the right options.